Exane Derivatives
- SEC CIK
- 0001623883
- Latest filing
- Jul 12, 2022
NVCR holding history
NovoCure Ltd in every 13F filed by Exane Derivatives, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NVCR overviewAll 13F holders of NVCRFull Q2 2022 holdings
- Shares (Q2 2022)
- 3
- Value
- $208
- % of portfolio
- <0.1%
- Quarters held
- 6
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2022 | 3 | $208 | <0.1% | −786−99.6% | Reduced | Holders |
| Q1 2022 | 789 | $65.4K | <0.1% | −161−16.9% | Reduced | Holders |
| Q4 2021 | 950 | $71.3K | <0.1% | −284−23.0% | Reduced | Holders |
| Q3 2021 | 1,234 | $143.3K | <0.1% | −204−14.2% | Reduced | Holders |
| Q2 2021 | 1,438 | $271.0K | 0.1% | −452−23.9% | Reduced | Holders |
| Q1 2021 | 1,890 | $249.8K | 0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.